A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 2, 2007, Pages 133-138

  Chow, Louis Wing Cheong ^a,b   Yip, Adrian Yun San ^a   Lang, Brian Hung Hin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Luk Kwok Centre   (Hong Kong)

Author keywords

Breast cancer; Liposomal doxorubicin; Metastases; Vinorelbine

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; DOXORUBICIN; NAVELBINE; TAXANE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT SELECTION; POLYETHYLENE GLYCOLS; POSTMENOPAUSE; PREMENOPAUSE; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 34147127552     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000251400.47711.fe     Document Type: Article

References (30)

1. Minami Y, Tsubono Y, Nishino Y, et al. The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer. 2004;108:901-906.
2. Ahn SH, Korean Breast Cancer Society. Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg. 2004;139:27-30.
3. Gairard B, Mathelin C, Schaffer P, et al. Breast cancer: epidemiology, risk factors, screening. Rev Prat. 1998;48:21-27.
4. Honig SF. Hormonal therapy and chemotherapy. In: Harris JR, Morrow M, Lippman ME, et al, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven; 1996:669-734.
5. Hortobagyi GN. Anthracyclines in the treatment of cancer. Drugs. 1997;54:1-7.
6. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997;15:1333-1340.
7. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318-1332.
8. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333-3355.
9. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 1989;63:37-45.
10. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs. 1997;54:30-35.
11. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89:1037-1047.
12. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (CAELYX/Doxil) versus conventional doxorubicin for firstline treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.
13. Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004;22:3893-3901.
14. Spielmann M, Dorval T, Turpin F, et al. Phase II trial of vinorebline/ doxorubicin as first line therapy of advanced breast cancer. J Clin Oncol. 1994;12:1765-1770.
15. Weber BL, Vogel C, Jones S, et al. Intravenous vinorebline as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995;13:2722-2730.
16. Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995;13:2567-2574.
17. Livingston RB, Ellis GK, Gralow JR, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997;15:1395-1400.
18. Gebbia V, Mauceri G, Fallica G, et al. Peyglated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. Oncology. 2002;63:23-30.
19. Common Terminology Criteria for Adverse Events v2. 0 (CTCAE). National Cancer Institute. Available at: http://ctep.cancer.gov/forms/CTCv20_4-30-992. pdf. Accessed April 30,1999.
20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
21. Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001;6:133-146.
22. Zelek L, Cottu P, Tubiana-Hulin M, et al. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol. 2002;20:2551-2558.
23. Morabito A, Filippelli G, Palmeri S, et al. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. Breast Cancer Res Treat. 2003;78:29-36.
24. Gori S, Colozza M, Mosconi AM, et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer. 2004;90:36-40.
25. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40:536-542.
26. Razis E, Kosmidis P, Aravantinos G, et al. Second line chemotherapy with 5-fuorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer. Cancer Invest. 2004;22:10-15.
27. Martin M, Garcia-Donas J, Casadp A, et al. Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin Breast Cancer. 2004;5:353-357.
28. Burstein HJ, Ramirez MJ, Petros WP, et al. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999;10:1113-1116.
29. Jahanzeb M, Hirsh R. Phase I study of Doxil R in combination with escalating doses of Navelbine R for the treatment of patients with advanced malignancies. Proc Am Soc Clin Oncol. 1999;18:215.
30. Rimassa L, Carnaghi C, Garassino I, et al. Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat. 2003;77:185-188.